[Second prevention following myocardial infarct].
The prophylactic effect of beta-blockers in reducing reinfarction and cardiac death after acute myocardial infarction has been proven convincingly in several studies. Whereas anticoagulation is not generally accepted in secondary prophylaxis, it has been shown that in patients where treatment with anticoagulants could be performed without difficulty, withdrawal of the drug is disadvantageous. Large-scale studies have shown the relatively slight effect of drugs which inhibit platelet aggregation. The indication for these drugs, and "prophylactic" surgery to improve prognosis, are discussed with respect to the various risk groups.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control* / Q000601:surgery; D010974:Platelet Aggregation / Q000187:drug effects; D012008:Recurrence
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D001241:Aspirin
Die Sekundärprophylaxe nach Myokardinfarkt.